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Summary
Background High body-mass index (BMI; deﬁ ned as 25 kg/m² or greater) is associated with increased risk of cancer. 
To inform public health policy and future research, we estimated the global burden of cancer attributable to high BMI 
in 2012.
Methods In this population-based study, we derived population attributable fractions (PAFs) using relative risks and 
BMI estimates in adults by age, sex, and country. Assuming a 10-year lag-period between high BMI and cancer 
occurrence, we calculated PAFs using BMI estimates from 2002 and used GLOBOCAN2012 data to estimate numbers 
of new cancer cases attributable to high BMI. We also calculated the proportion of cancers that were potentially 
avoidable had populations maintained their mean BMIs recorded in 1982. We did secondary analyses to test the 
model and to estimate the eﬀ ects of hormone replacement therapy (HRT) use and smoking.
Findings Worldwide, we estimate that 481 000 or 3·6% of all new cancer cases in adults (aged 30 years and older after 
the 10-year lag period) in 2012 were attributable to high BMI. PAFs were greater in women than in men (5·4% vs 
1·9%). The burden of attributable cases was higher in countries with very high and high human development indices 
(HDIs; PAF 5·3% and 4·8%, respectively) than in those with moderate (1·6%) and low HDIs (1·0%). Corpus uteri, 
postmenopausal breast, and colon cancers accounted for 63·6% of cancers attributable to high BMI. A quarter (about 
118 000) of the cancer cases related to high BMI in 2012 could be attributed to the increase in BMI since 1982.
Interpretation These ﬁ ndings emphasise the need for a global eﬀ ort to abate the increasing numbers of people with 
high BMI. Assuming that the association between high BMI and cancer is causal, the continuation of current patterns 
of population weight gain will lead to continuing increases in the future burden of cancer.
Funding World Cancer Research Fund International, European Commission (Marie Curie Intra-European Fellowship), 
Australian National Health and Medical Research Council, and US National Institutes of Health.
Copyright ©2014. World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved.
Introduction
High body-mass index (BMI; deﬁ ned as 25 kg/m² or 
greater) is a known risk factor for various chronic 
diseases and mortality. Although prevalence varies 
widely, overweight and obesity have been increasing 
worldwide, raising concerns about their eﬀ ect on health. 
Recent statistics showed that 35% of the adult population 
(aged 20 years and older) worldwide is overweight (BMI 
≥25 kg/m²), including 12% that is classiﬁ ed as obese 
(BMI ≥30 kg/m²).1 The prevalence of high BMI ranges 
from about 10% in many Asian and African countries to 
more than 90% in Paciﬁ c island nations such as the Cook 
Islands and Nauru. According to recent estimates,1,2 the 
global prevalence of excess bodyweight in adults 
increased by 27·5% between 1980 and 2013, although the 
increase has slowed in recent years in some European 
countries and the USA.3–7
Continuous updates of the scientiﬁ c literature have 
conﬁ rmed the association between high BMI and risk of 
oesophageal adenocarcinoma and colon, rectal, kidney, 
pancreas, gallbladder (women only), postmenopausal 
breast, ovarian, and endometrial cancers.8–13 The estimated 
increase in risk of these cancers due to high BMI ranges 
from 3% to 10% per unit increase in BMI.14 A recent 
estimate from Global Burden of Disease (GBD) study15 
showed that 3·9% of cancer mortality in 2010 could be 
attributed to high BMI. However, this estimate did not take 
into account the lag time necessary for high BMI to lead to 
the development of a new cancer. Additionally, relating risk 
factors to mortality in the estimation of disease burden can 
be problematic because of the potential role of reverse 
causation.16 Potential confounders and eﬀ ect modiﬁ ers of 
the association between BMI and cancer, such as the use of 
hormone replacement therapy (HRT) and smoking, also 
need to be taken into account.17,18
In this study, we aimed to estimate the global population 
attributable fraction (PAF) of cancer incidence in 2012 
attributable to high BMI in 2002, acknowledging the time 
lag between the exposure (high BMI) and outcomes 
(cancer incidence). We also aimed to test the robustness of 
the estimates in a series of sensitivity analyses, including 
assessment of the role of smoking and HRT use as 
potential eﬀ ect modiﬁ ers or confounders of the association 
between high BMI and cancer incidence.
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Methods
Study design
In this population-based study, we quantiﬁ ed the eﬀ ect of 
high BMI on cancer incidence in the adult population 
worldwide, tested the eﬀ ect of various model 
assumptions, and assessed the eﬀ ect of confounders and 
eﬀ ect modiﬁ ers. We applied PAFs according to sex, age, 
cancer site, and country to national estimates of cancer 
incidence estimates, using data for mean BMI, cancer 
incidence, and corresponding risk estimates. 
We used the BMI estimates reported by Global Burden 
of Metabolic Risk Factors of Chronic Diseases 
Collaborating Group.1 The details of the applied model 
and its assumptions in the estimation of mean BMIs 
have been reported elsewhere.19 For this study, we 
obtained the annual estimates of mean BMI and the 
corresponding SDs for adults aged 20 years and older 
for each country by sex and age group (20–34, 35–44, 
45–54, 55–64, 65–74, and ≥75 years) in 1982 and 2002 
(appendix pp 2–7).
In our primary analysis, we included only cancers 
reported by the World Cancer Research Fund (WCRF) as 
having suﬃ  cient evidence to be associated with high 
BMI.8–13 These include oesophageal adenocarcinoma and 
colon, rectal, kidney, pancreatic, gallbladder, post-
menopausal breast, corpus uteri, and ovarian cancers, 
collectively deﬁ ned here as high-BMI-related cancers. In 
view of the diﬀ erences in risk of colon and rectal cancer 
associated with obesity, we estimated PAFs for these two 
cancer sites separately. Similarly, only adenocarcinoma of 
the oesophagus was included because of the absence of an 
association between excess bodyweight and oesophageal 
squamous-cell carcinoma.
The sex-speciﬁ c relative risks (RRs) for the sites included 
in the analysis were obtained from the standardised meta-
analysis estimates by Renehan and colleagues14 and the 
WCRF Continuous Update Project.8–13 In these meta-
analyses, risk estimates were pooled from from cohort 
studies that mainly used cancer incidence as an outcome 
(apart from pancreatic cancer, for which studies included 
mortality as an outcome). In a secondary analysis we 
included thyroid cancer and non-Hodgkin lymphoma as 
additional cancer sites, which might be associated with 
high BMI,14,20 but were not listed by WCRF as having 
suﬃ  cient evidence. The exact sources and sizes of RRs are 
described in the appendix (pp 8–9).
Calculation of PAF
We calculated PAFs on the basis of the approach 
suggested by the Comparative Risk Assessment 
Collaborative Group, using the formula:21
where P(x) is the population distribution of BMI, P*(x) is 
the distribution of theoretical minimum BMI, RR(x) is 
the RR of cancer associated with BMI, and dx indicates 
that the integration was done with respect to BMI. The 
theoretical minimum distribution of BMI was deﬁ ned as 
a BMI distribution with a mean of 22 kg/m² and an SD 
of 1 kg/m², at which the disease burden is assumed to be 
lowest at the population level.15,22
We used a log-logit function to characterise the shape 
of the RR across BMI units. Furthermore, we assumed 
no risk for BMI less than 22 and no risk increase for BMI 
greater than 40, since estimates of RR beyond these 
points were scant. A pictorial illustration and a more 
detailed description of these assumptions of the risk 
function are presented in the appendix (pp 8–9).
We calculated age-speciﬁ c, sex-speciﬁ c, and country-
speciﬁ c PAFs for individual high-BMI-related cancer 
sites. We then derived the number of cancer cases 
attributable to high BMI by multiplying age-speciﬁ c, sex-
speciﬁ c, country-speciﬁ c, and cancer-speciﬁ c PAFs by the 
corresponding numbers of incident cancers in 2012. We 
calculated overall national, regional, and global estimates 
of the total attributable proportion of cancer related to 
high BMI by summing the numbers of attributable 
incident cases and dividing them by the total number of 
cancer cases in each subgroup.
We estimated 90% uncertainty limits for PAFs using 
Monte Carlo simulation. We also computed a counter-
factual scenario (ie, a model of incidence if mean BMIs 
had remained at their 1982 values) to provide a more 
realistic view about the preventable proportion of the 
current burden of cancers caused by high BMI. The 
analysis was done by replacing the theoretical minimum 
distribution with the BMI distribution that was reported 
in in 1982, an attainable value in the past in each country 
and probably a more realistic goal for prevention than 
the mean BMI of 22 kg/m² used in our main analysis. 
Using this approach, we estimated what the PAF would 
be if population mean BMIs had stayed constant at their 
1982 values. A more detailed description of PAF inputs 
and calculation is presented in the appendix (pp 31–33).
Cancer incidence and attributable cancer burden
The numbers of incident cancers in 2012 by age (in adults 
aged 30 years and older after 10-year lag period), sex, and 
country were obtained from GLOBOCAN 2012.23 
Countries were grouped into 12 geographical regions 
(appendix pp 34–40): sub-Saharan Africa (eastern, middle, 
southern, and western Africa); Middle East and north 
Africa (western Asia and northern Africa); Latin America 
and the Caribbean (central and south America and the 
Caribbean); North America; east Asia (eastern Asia, 
including China); southeast Asia; south-central Asia 
(southern Asia, including India); eastern Europe; 
northern Europe; southern Europe; western Europe; and 
Oceania (including Australia and New Zealand).24 
Furthermore, countries also were grouped by 2012 
human development index (HDI; very high, high, 
moderate, or low).25 Because the separate incidences of 
See Online for appendix
PAF=
∫RR(x)P(x)dx – ∫RR(x)P*(x)dx
∫RR(x)P(x)dx
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colon and rectal cancers and the incidence of oesophageal 
cancer by histological subtypes are not reported in 
GLOBOCAN,23 we estimated the numbers of these 
cancers by subtypes using country-speciﬁ c and sex-
speciﬁ c proportions of subtypes reported in Cancer 
Incidence in Five Continents volume X (appendix p 10).26,27
The precise time lag between development and 
duration of high BMI and the occurrence of cancer is not 
well established. However, the general perception is that 
excess bodyweight does not initiate cancer, but rather 
promotes of cancer to clinical presentation over several 
years. Renehan and colleagues28 assumed a 10-year lag 
time on the basis of the scientiﬁ c literature, wherein the 
average follow-up time of 10 years showed the beneﬁ cial 
eﬀ ect of weight loss on subsequent cancer risk.29,30 With 
no additional information available, we chose to assume 
a 10-year lag period in this study, mapping high BMI 
prevalence in 2002 (by sex, age, and country) to cancer 
incidence in 2012.
Sensitivity analyses
In estimating the PAFs of cancers attributable to high 
BMI, we made several assumptions about the population 
BMI distribution and the RRs function. To assess their 
eﬀ ect on the results, we repeated the analyses while 
changing the following assumptions: exposure deﬁ nition 
(categorical vs continuous BMI; appendix pp 13–14); BMI 
distribution (normal vs log-normal; appendix pp 15–16); 
shape of the RR (linear or log-linear vs log-logit; appendix 
pp 17–19); and region-speciﬁ c versus global RR estimates 
(appendix pp 20–23). Because smoking31–34 and use of 
HRT8,11,35 are known eﬀ ect modiﬁ ers of the association 
between bodyweight and cancer, we estimated PAFs 
stratiﬁ ed by current smoking status (for pancreatic 
cancer) or HRT use (for postmenopausal breast cancer, 
ovarian cancer, and endometrial cancer) and assessed the 
bias that might have occurred when these interactions 
were ignored (appendix pp 24–27). Furthermore, because 
studies have shown a protective eﬀ ect of high BMI on 
premenopausal breast cancer,8,14,36 we also assessed the 
potentially adverse eﬀ ects of decreasing population BMI 
on the incidence of premenopausal breast cancer and its 
eﬀ ect on the total PAF (appendix pp 28–30).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Worldwide, our result show that an estimated 481 000 or 
3·6% of all new cancers (or 12·8% of all high-BMI-
related cancers) in adults in 2012 were attributable to 
high BMI. By sex, 136 000 (1·9%) new cancers in men 
(table 1) and 345 000 (5·4%) in women (table 2) were 
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attributable to high BMI. The attributable burden was 
larger in countries with very high and high HDIs (PAF 
5·3% and 4·8%, respectively) than in those with 
moderate (1·6%) and low (1·0%) HDIs.
Region-speciﬁ c estimates show that all three Asian 
regions and sub-Saharan Africa had the lowest PAFs, 
ranging from 0·4% to 0·9% of total cancers (3·6% to 
6·0% of total high-BMI-related cancers) in men and 
1·7% to 3·0% of total cancers (5·4% to 8·3% of total 
high-BMI-related cancers) in women. North America 
had the highest PAFs, at 3·5% of total cancers (20·8% of 
high-BMI-related cancers) for men and 9·4% of total 
cancers (19·2% of high-BMI-related cancers) for women. 
For the remaining regions (Middle East and north Africa, 
Latin America and the Caribbean, Oceania, and all 
European regions), the PAF ranged from 2·0% to 9·9% 
of total cancers (14·4% to 18·2% of high-BMI-related 
cancers) in both sexes.
With respect to the regional contribution to new high-
BMI-related cancers in 2012, the North American region 
contributed the most (111 000 or 23·0% of the total 
worldwide cases attributable to high BMI), and sub-
Saharan Africa the least (7300 or 1·5%; tables 1, 2). 
Eastern Europe had the greatest share of attributable 
PAF (%)
 3·1–<5·5 
 2·0–<3·1
 1·0–<2·0
 0·3–<1·0
 0·0–<0·3
 No data
Men
Women
PAF (%)
 8·5–<12·7
 6·6–<8·5
 3·9–<6·6
 1·6–<3·9
 0·4–<1·6
 No data
Figure 1: PAF of new cancer cases in 2012 caused by high BMI in men and women, by country
PAF=population attributable fraction.
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burden among the European regions (66 000 or 33·8% of 
the total European cases attributable to high BMI). 
Despite the low PAF (1·8%), the east Asia region had the 
second largest number of cases attributable to high BMI 
(70 000) after North America, because of its large 
population size.
Country-speciﬁ c PAFs for men and women are shown 
in ﬁ gure 1 and in the appendix (pp 34–40). In men, the 
highest PAF of 5·5% was in the Czech Republic, 
followed by 4·5% in Jordan and Argentina, and 4·4% in 
the UK and Malta. The greatest between-country 
diﬀ erences within a region were in Latin America and 
the Caribbean, where the PAF ranged from 4·5% in 
Argentina to 0·7% in Haiti and Jamaica. In women, 
Barbados had the highest PAF, with 12·7% of cancers 
attributable to high BMI, followed by the Czech 
Republic (12·0%) and Puerto Rico (11·6%). As for men, 
between-country diﬀ erences were largest in Latin 
America and the Caribbean, where the PAF ranged 
from 12·7% in Barbados to 1·6% in Haiti. Countries in 
sub-Saharan Africa had consistently lower overall PAFs 
than those in other regions, of less than 2% in men and 
less than 4% (with the exception of Mauritius and South 
Africa) in women.
PAF also varied greatly by cancer site, ranging from 
6·2% for rectal cancer to 33·3% for oesophageal 
adenocarcinoma in men and from 3·6% for rectal cancer 
to 34·0% for cancer of the corpus uteri and oesophageal 
adenocarcinoma in women (tables 1, 2). Despite having a 
large estimated PAF of more than 30%, oesophageal 
adenocarcinomas accounted for only 14 000 (or 10·0%) of 
the total worldwide cancer cases attributable to high BMI 
in men and 4000 (or 1·1%) in women. Colon cancer in 
men and postmenopausal breast cancer in women 
contributed the largest number of cancer cases 
attributable to high BMI. In men, colon and kidney 
cancer together contributed about two-thirds of the new 
cancer cases attributable to high BMI (90 000). In women, 
postmenopausal breast cancer and cancer of the corpus 
uteri contributed about two-thirds of the new cancer 
cases attributable to high BMI (221 000).
We noted substantial diﬀ erences between men and 
women in PAFs for colon cancer (13·0% vs 7·6%). Sex 
diﬀ erences in the numbers of attributable cases were 
largest for colon cancer and oesophageal adeno-
carcinoma, with 56 000 and 14 000 attributable cases, 
respectively in men and only 29 000 and 4000 attributable 
cases in women (tables 1, 2). The incidence of high-
BMI-related cancers attributable to high BMI was 
relatively higher for women than for men in all regions 
(ﬁ gure 2). Particularly, in regions with a fairly low 
incidence of high-BMI-related cancers, such as Asia and 
sub-Saharan Africa, the proportion of new cancer cases 
attributable to high BMI was two to three times greater 
for women than for men.
In our counterfactual scenario, we calculated that if 
BMI had remained as recorded in 1982, about a quarter 
(118 000 cases) of cases of high-BMI-related cancers in 
2012 could have been averted. In other words, a quarter of 
all high-BMI-related cancers could be attributed to the 
increase in BMI between 1982 and 2002 (appendix 
pp 31–33). About 0·9% (0·5% in men and 1·3% in 
women) of all cancers diagnosed in 2012 could therefore 
be regarded as realistically avoidable by prevention of 
high BMI. The realistically attributable fraction was 
greatest in countries with a very high or high HDI, where 
83·2% of these potentially avoidable cancers occurred. In 
a high-burden region such as North America, this 
proportion translated into more than 40 000 cases, or 
35·6% of all attributable cancer cases that could be linked 
to the increase in BMI since 1982. With respect to speciﬁ c 
cancer sites, about 10·7% of all oesophageal adeno-
carcinomas (5600), 8·5% of all corpus uteri (27 000), 
4·9% of all kidney (15 000) and 2·5% of all postmenopausal 
breast cancers (28 000) could have been avoided if BMI 
had not increased between 1982 and 2002.
North America
Northern Europe
Western Europe
Oceania
Southern Europe
Eastern Europe
Latin America and the Caribbean
Middle East and north Africa
East Asia
Southeast Asia
Sub-Saharan Africa
South-central Asia
352·4
330·6
315·9
299·0
269·2
250·1
170·7
140·4
125·6
109·7
86·2
76·1
58·2
42·7
38·7
40·0
35·2
38·5
23·4
21·8
9·7
6·5
6·2
3·9
153·8
160·0
166·3
164·8
153·2
143·3
63·6
53·9
80·7
44·4
20·6
22·1
26·7
24·9
24·3
25·2
21·4
17·4
8·1
6·9
4·6
1·5
1·0
0·8
200 4003002001000100
Incidence rate
Men
Women
Figure 2: Age-standardised incidence rate of high-BMI-related cancers and high-BMI-related cancers attributable to high BMI (per 100 000 people) in 2012
Incidence data are age-standardised to the world standard population. Light bars show total incidence rates of high-body-mass-index (BMI)-related cancers, and dark 
bars show those attributable to high BMI.
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When PAF for pancreatic cancer was corrected for 
smoking status, we estimated that it ranged between 0·6% 
and 18·3% for both men and women (appendix pp 24–25), 
dependent on country. Compared with the unadjusted 
PAFs, this adjustment increased the PAF by 0–5 percentage 
points in men and 0–9 percentage points in women. This 
diﬀ erence was largest in the UK for both men and women. 
HRT non-users had substantially higher PAFs than HRT 
users; PAFs for HRT non-users ranged from 50·4% to 
65·0% for corpus uteri cancer and from 8·3% to 12·4% 
for postmenopausal breast cancer and ovarian cancer, 
dependent on country. For HRT users, we noted PAFs 
between 8·6% and 20·8% for corpus uteri cancer and 
PAFs below 0% for postmenopausal breast and ovarian 
cancers, because of slightly protective RRs (appendix 
pp 26–27). When comparing the PAFs corrected for HRT 
use to the unadjusted PAFs, the diﬀ erence was small for 
most countries, ranging from 0 to 14 percentage points for 
corpus uteri cancer and from 0 to 5 percentage points for 
postmenopausal breast and ovarian cancers. The diﬀ erence 
was larger in countries where the prevalence of HRT use 
was low (<55%) and a large proportion of women had high 
BMI—eg, Germany and Russia.
The results for thyroid cancer, non-Hodgkin lymphoma, 
and premenopausal breast cancer are reported in the 
appendix (pp 28–30). In the sensitivity analyses, the 
choice of BMI data type and distribution did not 
substantially aﬀ ect the results (appendix pp 13–16), 
although PAFs changed with the use of diﬀ erent RR 
functions (appendix pp 17–19) and region-speciﬁ c RRs 
(appendix pp 20–23).
Discussion
Our results show that about 3·6% of all new cancers in 
adults aged 30 years and older (excluding non-melanoma 
skin cancer) in 2012, or 12·8% of high-BMI-related 
cancers, could be attributed to high BMI. These ﬁ gures 
are equivalent to an estimated 481 000 new cancers that 
might have been caused by high BMI. Postmenopausal 
breast, corpus uteri, and colon cancer accounted for 
72·5% of the total attributable cases in women, whereas in 
men kidney and colon cancers accounted 66·0% of all 
attributable cases. 63·5% of the global cancer cases related 
to high BMI were in the North American and European 
regions, although the PAF was also large in Oceania, Latin 
America and the Caribbean, and the Middle East and 
north Africa. Assuming that the association between high 
BMI and cancer is causal, the continuation of current 
patterns of population weight gain will lead to continuing 
increases in the future burden of cancer. Most importantly, 
about one quarter of the total cases attributable to high 
BMI (118 000 cancers) could potentially have been avoided 
if the global population mean BMI had remained the 
same as was recorded in 1982.
Our results show that the issue of cancer burden related 
to high BMI mainly aﬀ ects higher-resource regions, 
particularly North America and Europe. Besides the 
unequal distribution of cancer cases attributable to high 
BMI worldwide, we noted substantial diﬀ erences within 
regions; for example, in Latin America and the Caribbean 
PAFs for women ranged from 12·7% in Barbados to 1·6% 
in Haiti. Although high-BMI-related cancers have become 
a global issue,37 the transition from increasing, to 
stabilising, to possibly decreasing obesity prevalence 
occurs at diﬀ erent rates in diﬀ erent countries and 
regions. In a few countries such as the UK and the USA, 
where BMI increased substantially in the 1980s and 
1990s, the BMI increase has since slowed, but in most 
countries the average BMI has continued to increase 
steadily since the 1980s.2
The results of our secondary analysis, in which historical 
BMI was used as an achievable population mean BMI, 
could be used to measure the changing eﬀ ect of BMI on 
the burden of cancer. Taking into account both current 
population mean BMIs and their changes over time, the 
increase in PAF has been greatest in the Middle East and 
north Africa, Latin America and the Caribbean, North 
America, and Oceania. By contrast, eastern Europe 
maintained a similar (high) population mean BMI 
between 1982 and 2002, so despite the large current PAF, 
only very few cases are attributable to the change in BMI in 
that period. The varying pattern in BMI distribution and 
trends across countries emphasises the need for future 
research into the cumulative eﬀ ects of overweight and 
obesity on the burden of cancer and other chronic diseases.
Investigators of independent pooled studies31–33 have 
reported an attenuated risk of high BMI in smokers for 
pancreatic and thyroid cancers. In our study, taking into 
account the diﬀ erential eﬀ ect by smoking status produced 
diﬀ erent estimates, dependent on a country’s smoking 
prevalence. In high-income countries such as the UK and 
the USA, because of the high past prevalence of tobacco 
smoking38 and high present BMI,1 the PAF of pancreatic 
cancer related to high BMI was slightly underestimated in 
our uncorrected analysis. By contrast, in low-income 
countries such as Ghana, where smoking prevalence has 
only started to rise,39 the eﬀ ect of high BMI on pancreatic 
cancer was slightly overestimated or was not large enough 
to be appreciable. Another important eﬀ ect modiﬁ er in 
the relation between BMI and cancer is HRT use, wherein 
the risk of female hormone-driven cancers related to high 
BMI is largely attenuated or even eliminated among HRT 
users.8,11,35 In our sensitivity analysis, we showed that most 
postmenopausal breast, ovary, and corpus uteri cancers 
attributable to high BMI occurred among HRT non-users. 
The falling use of HRT since the early 2000s40,41 has 
contributed to a decrease in breast cancer incidence in 
countries where use was high; this decrease in use will 
probably translate into a higher proportion of cases being 
attributable to high BMI and therefore amenable to 
prevention by weight loss.
This study adds important insights to the contribution 
of lifestyle and exogenous risk factors on cancer risk. 
Previous studies have quantiﬁ ed the global cancer burden 
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attributable to infections (2 million new cases in 2008, 
PAF 16·1%)42 and smoking (1·4 million cancer deaths in 
2000, PAF 21%).43 Ours is the most comprehensive study 
so far reported to provide worldwide estimates of the 
burden of cancer due to high BMI (panel).
A report from the GBD study15 provided estimates of 
the burden of cancer due to high BMI, but those results 
are not directly comparable to ours because PAF was 
presented as a proportion of deaths or disability-adjusted 
life years attributable to high BMI, whereas incidence was 
the outcome in our study. Furthermore, in the GBD study, 
information about high BMI prevalence and cancer 
mortality was obtained for the same year, not allowing for 
a lag between the exposure and cancer development and 
mortality. A few other studies have provided estimates of 
cancer incidence associated with high BMI,17,28,44–46 but 
these were limited to European populations. For example, 
Renehan and colleagues28 estimated that 2·5% of all 
cancer cases in men and 4·1% in women were related to 
high BMI. Our estimates for the European regions ranged 
between 3·1% and 3·8% in men and between 7·8% and 
9·9% in women. Such diﬀ erences in estimates are to be 
expected, since our estimates are based on more recent 
data for both the prevalence of high BMI and the 
incidence of cancer, both of which have increased greatly 
over the past decade.19,47
Another strength of this study is the use of age-speciﬁ c, 
sex-speciﬁ c, and country-speciﬁ c estimates of BMI and 
the latest available estimates of cancer incidence. 
Although these data were estimates and therefore careful 
interpretation of the results is advised, the best available 
estimates were used. We made many assumptions when 
estimating the PAFs; however, our sensitivity analyses 
showed that changing these assumptions made little 
diﬀ erence to the reported PAFs. One of the assumptions 
that we tested was related to the evidence of non-linear 
associations between BMI and several cancers—eg, 
oesophageal, colon, breast, and endometrial cancers.44 
We opted for a log-logit RR function for all cancer sites 
included in this study instead of a linear function, which 
partly addressed this issue. In the sensitivity analyses, we 
tested diﬀ erent RR functions, which had only small 
eﬀ ects on the ﬁ nal PAF estimates.
Alongside point estimates for the PAF, we presented 
90% uncertainty intervals to provide a measure of 
reliability. However, these uncertainties do not take into 
account uncertainties in the cancer data from the 
GLOBOCAN 2012 database, which provides a qualitative 
ranking of data quality for each country-speciﬁ c estimate.23 
Quantiﬁ cation of this uncertainty and incorporation of 
additional uncertainties from the modelling and 
estimation processes remains a major challenge and 
therefore was not attempted in our analysis.48,49
Another limitation of this study includes the 
assumption of constant RRs across very diverse popu-
lations. The risks of some cancers associated with excess 
bodyweight have been reported to vary by ethnic group 
and geographical location.14,50 Variation exists in the 
distribution of body fat between ethnic groups and how 
this is reﬂ ected in the BMI measure. For example, within 
the USA, African-American and Hispanic women are 
more likely to be obese than white and Asian-American 
women, yet white and Asian-American women have 
higher body fatness at similar BMIs.51 Other 
anthropometric measures, such as waist circumference 
or waist-to-hip ratio, have been suggested as better 
predictors of obesity-related health outcomes than 
BMI.52,53 Furthermore, rural and urban diﬀ erences in the 
prevalence of obesity have been reported.54–56 In our study, 
some variation in the distribution of BMI between ethnic 
groups might have been captured by our use of country-
speciﬁ c BMI estimates. However, residual variation—ie, 
within countries—was not accounted for in the models. 
Because very little information is available for subnational 
populations such as ethnic groups and because of the 
absence of comparable global prevalence data for other 
anthropometric measures and their risk estimates, we 
could not do additional analyses to address these issues.
Another drawback is the assumption of the absence of 
time-dependent eﬀ ects of high BMI on cancer risk, 
which cannot be completely captured by age-speciﬁ c 
BMI data and lag time. We assumed a 10-year lag in our 
modelling, but we recognise that the time-related eﬀ ects 
of excess adiposity are likely to vary between cancer types. 
Results from some studies57,58 have shown that the risk of 
cancer from high BMI accumulates with the number of 
years lived with excess weight, suggesting that the risk 
can better be predicted from years of life lived with high 
BMI. Longer duration of obesity has also been linked to 
other diseases and conditions, such as coronary artery 
Panel: Research in context
Systematic review
We searched Medline for articles published in any language up to Jan 1, 2014, using the 
search terms “obesity”, “body-mass index”, “cancer risk”, “cancer incidence”, “attributable 
fraction”, “avoidable”, and “preventable”. We identiﬁ ed several studies that provided 
estimates of the burden of cancer attributable to high body-mass index (BMI) in speciﬁ c 
countries or regions,17,28,44–46 as well as a report15 from the Global Burden of Disease study 
that included estimates of deaths or disability-adjusted life years attributable to high BMI. 
However, no previous study had provided global estimates of cancer incidence 
attributable to high BMI.
Interpretation
Our results show that 3·6% of all new cancers in adults in 2012 (a total of 481 000 cases) 
are attributable to excess bodyweight. This ﬁ nding emphasises the need for a global eﬀ ort 
to abate the continuing increases in overweight and obesity worldwide. Assuming a 
causal link between high BMI and cancer incidence, if the current pattern of population 
weight gain continues, it will lead to further increases future burden of cancer, especially 
in regions such as Latin America and the Caribbean and north Africa, where the largest 
increases in the prevalence of obesity have occurred in the past three decades.2 Our results 
should be used to inform health policy in terms of targets for prevention programmes, 
while emphasising existing gaps in our knowledge about the association between BMI 
and cancer.
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calciﬁ cation, a precursor of coronary heart disease.59 
Although this ﬁ nding is in line with the biological 
mechanisms underlying the association between obesity 
and the development cancer, studies examining this 
aspect of obesity are a recent development and neither 
risk estimates nor the exposure information are available 
for every type of high-BMI-related cancer.
Lastly, the estimation of the PAF is based on the 
assumption that the association between high BMI and 
each cancer type included in our study is causal.60 We 
thus assume that reducing BMI will lead to a reduction 
in the incidence of these cancers. Excess bodyweight has 
been shown to increase circulating levels of oestrogens 
and bioactivity of IGF-1, hence promoting the 
development of cancer.61 However, epidemiological 
studies that report risk associations between BMI and 
cancer are prone to several limitations. Residual 
confounding might account for the association between 
obesity and some types of cancer, and this possibility was 
not accounted for in our analysis. We have tried to 
overcome this issue by exclusively using risk estimates 
based on large meta-analyses that included only high-
quality studies and, whenever possible, only cohort 
studies.
Based on our results, historical and continuing 
increases in the global prevalence of high BMI, especially 
in younger cohorts, are expected to translate into further 
increases in cancer burden in the future. Changes in the 
prevalence of strong eﬀ ect modiﬁ ers such as HRT use 
are likely to increase the proportions of cancers 
attributable to high BMI, particularly among women. 
The large burden of cancers attributable to high BMI in 
North America, Europe, Oceania, Latin America and the 
Caribbean, and the Middle East and north Africa points 
to the importance of weight-control programmes in these 
regions. Our results should inform health policy in terms 
of targets for prevention programmes, while emphasising 
existing gaps in our knowledge about the association 
between BMI and cancer. It also emphasises the need for 
research into eﬀ ective interventions to control weight 
gain to avoid further increases in the burden of cancer 
related to high BMI.
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